Skip to main content
Equibles
ALUR logo

ALUR · Allurion Technologies, Inc. · Metrics

Track ALUR — free

Use ALUR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALUR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.39 -0.29 (-42.62%) At close · Mar 9
Rebalance outlook locked
Going-concern doubt — flagged May 15, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the amount and timing of such financings are uncertain, the Company has concluded that management’s plans do not alleviate substantial doubt about its ability to continue as a going concern for a reasonable period of time.”
View the 10-Q filed May 15, 2026
Market Cap
$2.01M
Shares
1.00M
Volume · Mar 9 392.2K Avg daily vol (3M) —

ALUR metrics

57 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.39
Market cap
$2.01M

Price action

20 metrics
Price change (1W)
-45.1%
Price change (30D)
—
Price change (3M)
-77.1%
Price change (6M)
-82.3%
Price change (YTD)
-68.7%
Price change (1Y)
-84.2%
Trailing year
Price change (5Y)
—
52-week high
$3.58
52-week low
$0.39
Change from 52-week high
-89.2%
Change from 52-week low
+0.0%
Annualized volatility
137.7%
Annualized volatility (3M)
205.4%
Beta
1.3
RSI (14D)
30.1
Price vs SMA 50
-70.5%
Price vs SMA 200
-80.6%
Avg volume (3M)
2.64M
Relative volume
0.2
Average dollar volume
$4.37M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
1.00M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.2×
reciprocal yield 626.5%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,658.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-12

Profitability

9 metrics
Gross margin
52.7%
Operating margin
-211.2%
Trailing 12 months
Net margin
-264.7%
Gross profit (TTM)
$6.64M
Operating profit (TTM)
−$26.61M
Net income (TTM)
−$33.35M
Trailing 12 months
Diluted EPS (TTM)
$-3.96
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
$-19.06
Capital expenditures per diluted share (TTM)
$0.31
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-6.29

Growth

11 metrics
Revenue growth YoY
-47.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$12.60M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+179.4%
Year over year · more shares
Revenue CAGR (3Y)
-38.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-238.3%
Debt / equity
—
Current ratio
0.3
EBITDA (TTM)
−$25.66M
Free cash flow (TTM)
—
Quick ratio
0.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$5.06M
Total assets
$13.99M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$22.70M
Capital expenditures (TTM)
$611,000
R&D (TTM)
$5.86M
SG&A (TTM)
—
Stock compensation (TTM)
$2.89M
R&D / revenue
46.5%
Stock compensation / revenue
22.9%

Ownership (13F)

9 metrics
13F filers
1
13F filer change QoQ
-2
Institutional ownership
4.5%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1964979 CUSIP 02008G300 Visit website Investor relations